BMY Bristol-Myers Squibb Company

Healthcare · Drug Manufacturers - General

8 · Strong Momentum 9.0 · Strong Watch 16y streak

66.58

+0.00%

About the company

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

Website Annual reports (10-K)

3.78%

55.51%

2.52

136.0B

14.67

4.54

57.66

52-week range

66.6

low 42.5 high 68.6

Dividend deep dive

Bristol-Myers Squibb Company (BMY), operating in the Drug Manufacturers - General industry within the Healthcare sector, offers a dividend yield of 3.76%. This is below its 5-year average yield of 3.89%, but remains within its 5-year yield band of 2.96% to 4.89%, with Yield Theory indicating a "fair" valuation. The company holds an overall rating score of 8.0. It also shows strong price momentum with a score of 9.0 and a favorable value score of 8.3.

Dividend history

Bristol-Myers Squibb boasts a 16-year streak of dividend increases, earning it the Dividend Contender tier. The dividend has demonstrated robust growth, with a 3-year compound annual growth rate (CAGR) of 4.71% and a 5-year CAGR of 6.62%. Its Chowder number of 10.4 exceeds the 8.0 threshold. Annual dividends per share have consistently risen from $1.44 in 2014 to $2.28 in 2023, with a projected $2.40 for 2024 and $2.48 for 2025. This growth implies a dividend doubling time of 10.9 years.

Dividend safety

The dividend safety status for Bristol-Myers Squibb is currently rated as "watch." The company's payout ratio, based on its EPS, stands at 55.51%. Leverage metrics indicate a debt-to-equity ratio of 230.967.

Quantic · Free

Read the rest of the safety verdict

Plus the key risks and what to watch next — free, no card.

Try a sample portfolio Sign up free

AI-generated from Quantic's dividend data · Updated 24 Aug 2026 · Information, not financial advice.